• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

α-肌营养不良蛋白上核心M3的畸形是肌营养不良蛋白病的主要病因。

Malformations of Core M3 on α-Dystroglycan Are the Leading Cause of Dystroglycanopathies.

作者信息

Sharaf-Eldin Wessam

机构信息

Medical Molecular Genetics Department, National Research Centre, Cairo, Egypt.

出版信息

J Mol Neurosci. 2025 Feb 25;75(1):28. doi: 10.1007/s12031-025-02320-z.

DOI:10.1007/s12031-025-02320-z
PMID:39998573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11861012/
Abstract

Dystroglycanopathies (DGPs) are a group of autosomal recessive neuromuscular diseases with significant clinical and genetic heterogeneity. They originate due to defects in the O-mannosyl glycosylation of α-dystroglycan (α-DG), a prominent linker between the intracellular cytoskeleton and the extracellular matrix (ECM). Fundamentally, such interactions are crucial for the integrity of muscle fibers and neuromuscular synapses, where their defects are mainly associated with muscle and brain dysfunction. To date, biallelic variants in 18 genes have been associated with DGPs, where the underlying cause is still undefined in a significant proportion of patients. Glycosylation of α-DG generates three core motifs where the core M3 is responsible for interaction with the basement membrane. Consistently, all gene defects that corrupt core M3 maturation have been identified as causes of DGPs. POMGNT1 which stimulates the generation of core M1 is also associated with DGPs, as it plays a central role in core M3 processing. Other genes involved in the glycosylation of α-DG seem unrelated to DPGs. The current review illustrates the O-mannosylation pathway of α-DG highlighting the functional properties of related genes and their contribution to the progression of DPGs. Different classes of DPGs are also elaborated characterizing the clinical features of each distinct type and phenotypes associated with each single gene. Finally, current therapeutic approaches with favorable outcomes are addressed. Potential achievements of preclinical and clinical studies would introduce effective curative therapies for this group of disorders in the near future.

摘要

肌聚糖病(DGPs)是一组常染色体隐性神经肌肉疾病,具有显著的临床和遗传异质性。它们是由于α-肌聚糖(α-DG)的O-甘露糖基糖基化缺陷而引发的,α-DG是细胞内细胞骨架与细胞外基质(ECM)之间的一个重要连接物。从根本上说,这种相互作用对于肌纤维和神经肌肉突触的完整性至关重要,其缺陷主要与肌肉和大脑功能障碍有关。迄今为止,已有18个基因的双等位基因变异与DGPs相关联,但在相当一部分患者中,其潜在病因仍不明确。α-DG的糖基化产生了三个核心基序,其中核心M3负责与基底膜相互作用。一致的是,所有破坏核心M3成熟的基因缺陷都已被确定为DGPs的病因。刺激核心M1生成的POMGNT1也与DGPs相关,因为它在核心M3加工过程中起核心作用。其他参与α-DG糖基化的基因似乎与DPGs无关。本综述阐述了α-DG的O-甘露糖基化途径,突出了相关基因的功能特性及其对DPGs进展的贡献。还阐述了不同类型的DPGs,描述了每种不同类型的临床特征以及与每个单一基因相关的表型。最后,介绍了目前取得良好疗效的治疗方法。临床前和临床研究的潜在成果将在不久的将来为这组疾病引入有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c718/11861012/3d2caec6b1e7/12031_2025_2320_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c718/11861012/14cf6ba8fb7e/12031_2025_2320_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c718/11861012/3d2caec6b1e7/12031_2025_2320_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c718/11861012/14cf6ba8fb7e/12031_2025_2320_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c718/11861012/3d2caec6b1e7/12031_2025_2320_Fig2_HTML.jpg

相似文献

1
Malformations of Core M3 on α-Dystroglycan Are the Leading Cause of Dystroglycanopathies.α-肌营养不良蛋白上核心M3的畸形是肌营养不良蛋白病的主要病因。
J Mol Neurosci. 2025 Feb 25;75(1):28. doi: 10.1007/s12031-025-02320-z.
2
Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.哺乳动物中的核醇磷酸糖基化:O-甘露糖聚糖的新见解。
Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2462-2472. doi: 10.1016/j.bbagen.2017.06.024. Epub 2017 Jul 12.
3
Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan.肌膜弹性和骨骼肌健康需要肌营养不良蛋白聚糖的O-甘露糖基化。
Skelet Muscle. 2025 Jan 9;15(1):1. doi: 10.1186/s13395-024-00370-2.
4
Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.POMGnT1茎区的碳水化合物结合结构域调节α- dystroglycan的O-甘露糖基化位点。
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9280-5. doi: 10.1073/pnas.1525545113. Epub 2016 Aug 4.
5
Pikachurin interaction with dystroglycan is diminished by defective O-mannosyl glycosylation in congenital muscular dystrophy models and rescued by LARGE overexpression.Pikachurin 与 dystroglycan 的相互作用因先天性肌营养不良模型中 O-甘露糖基化缺陷而减弱,通过 LARGE 过表达得到挽救。
Neurosci Lett. 2011 Feb 1;489(1):10-5. doi: 10.1016/j.neulet.2010.11.056. Epub 2010 Dec 1.
6
Drosophila Dystroglycan is a target of O-mannosyltransferase activity of two protein O-mannosyltransferases, Rotated Abdomen and Twisted.果蝇肌营养不良蛋白聚糖是两种蛋白 O-甘露糖基转移酶,旋转体腹部和扭曲的 O-甘露糖基转移酶活性的靶标。
Glycobiology. 2010 Mar;20(3):381-94. doi: 10.1093/glycob/cwp189. Epub 2009 Dec 7.
7
[Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].[α- dystroglycanopathy(福山型先天性肌营养不良症、肢带型肌营养不良症等):糖基化异常与肌肉萎缩症]
Rinsho Shinkeigaku. 2005 Nov;45(11):932-4.
8
A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.一种新的肌营养不良聚糖病患者来源的 iPSC 模型验证了一种可增加 α- 肌营养不良聚糖糖基化的化合物。
EMBO Rep. 2019 Nov 5;20(11):e47967. doi: 10.15252/embr.201947967. Epub 2019 Sep 30.
9
Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.在新型肌营养不良聚糖病模型小鼠中,LARGE具有残余层粘连蛋白结合活性并增强了肌营养不良聚糖的糖基化。
Hum Mol Genet. 2009 Feb 15;18(4):621-31. doi: 10.1093/hmg/ddn387. Epub 2008 Nov 18.
10
High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of α-dystroglycan.α- dystroglycan 合成层粘连蛋白结合糖基表位的酶高度保守。
Open Biol. 2021 Sep;11(9):210104. doi: 10.1098/rsob.210104. Epub 2021 Sep 29.

本文引用的文献

1
Biological function of sialic acid and sialylation in human health and disease.唾液酸及唾液酸化在人类健康与疾病中的生物学功能
Cell Death Discov. 2024 Sep 30;10(1):415. doi: 10.1038/s41420-024-02180-3.
2
Glycosylation: mechanisms, biological functions and clinical implications.糖基化:机制、生物学功能和临床意义。
Signal Transduct Target Ther. 2024 Aug 5;9(1):194. doi: 10.1038/s41392-024-01886-1.
3
Oral ribose supplementation in dystroglycanopathy: A single case study.口服核糖补充剂治疗糖基化肌营养不良症:一项单病例研究。
JIMD Rep. 2024 Mar 4;65(3):171-181. doi: 10.1002/jmd2.12394. eCollection 2024 May.
4
Molecular mechanisms and therapeutic strategies for neuromuscular diseases.神经肌肉疾病的分子机制和治疗策略。
Cell Mol Life Sci. 2024 Apr 28;81(1):198. doi: 10.1007/s00018-024-05229-9.
5
Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone.全基因组和 RNA 测序将神经肌肉疾病的诊断率从单纯外显子组测序的 34%提高到 62%。
Ann Clin Transl Neurol. 2024 May;11(5):1250-1266. doi: 10.1002/acn3.52041. Epub 2024 Mar 27.
6
Prenatal diagnosis of Walker-Warburg syndrome: ultrasound, magnetic resonance imaging and three-dimensional reconstruction.沃克-沃伯格综合征的产前诊断:超声、磁共振成像及三维重建
Ultrasound Obstet Gynecol. 2024 Nov;64(5):699-701. doi: 10.1002/uog.27648. Epub 2024 Oct 12.
7
Long-read sequencing improves diagnostic rate in neuromuscular disorders.长读测序提高神经肌肉疾病的诊断率。
Acta Myol. 2023 Dec 20;42(4):123-128. doi: 10.36185/2532-1900-394. eCollection 2023.
8
Case Series on Autosomal Recessive Non-Syndromic Retinitis Pigmentosa Caused by POMGNT1 Mutations with a Report of a New Variant.POMGNT1突变导致的常染色体隐性非综合征性视网膜色素变性病例系列及一个新变异的报告
J Clin Med. 2023 Dec 7;12(24):7549. doi: 10.3390/jcm12247549.
9
Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.通过与核糖醇联合治疗肢带型肌营养不良2I型(LGMD2I)提高FKRP腺相关病毒(AAV)基因治疗的疗效。
Mol Ther. 2023 Dec 6;31(12):3478-3489. doi: 10.1016/j.ymthe.2023.10.022. Epub 2023 Nov 2.
10
GDP-Mannose Pyrophosphorylase B ()-Related Disorders.GDP-甘露糖焦磷酸化酶 B()相关疾病。
Genes (Basel). 2023 Jan 31;14(2):372. doi: 10.3390/genes14020372.